2020
Cause‐specific mortality after diagnosis of cancer among HIV‐positive patients: A collaborative analysis of cohort studies
Trickey A, May MT, Gill MJ, Grabar S, Vehreschild J, Wit F, Bonnet F, Cavassini M, Abgrall S, Berenguer J, Wyen C, Reiss P, Grabmeier‐Pfistershammer K, Guest JL, Shepherd L, Teira R, Monforte A, del Amo J, Justice A, Costagliola D, Sterne J. Cause‐specific mortality after diagnosis of cancer among HIV‐positive patients: A collaborative analysis of cohort studies. International Journal Of Cancer 2020, 146: 3134-3146. PMID: 32003460, PMCID: PMC7187452, DOI: 10.1002/ijc.32895.Peer-Reviewed Original ResearchConceptsCause-specific mortalityCause of deathMortality rateGeneral populationLymphoma diagnosisCancer diagnosisHodgkin lymphoma diagnosisHIV-positive patientsCause-specific mortality ratesDiagnosis of cancerHIV cohortCohort studyCervical cancerSurvival outcomesLung cancerPLHIVSpecific cancersCancerCancer typesDiagnosisMortalityDeathSurvivalNADMAIDS
2018
Benefits and harms of lung cancer screening in HIV-infected individuals with CD4+ cell count at least 500 cells/&mgr;l
Kong CY, Sigel K, Criss SD, Sheehan DF, Triplette M, Silverberg MJ, Henschke CI, Justice A, Braithwaite RS, Wisnivesky J, Crothers K. Benefits and harms of lung cancer screening in HIV-infected individuals with CD4+ cell count at least 500 cells/&mgr;l. AIDS 2018, 32: 1333-1342. PMID: 29683843, PMCID: PMC5991188, DOI: 10.1097/qad.0000000000001818.Peer-Reviewed Original ResearchConceptsLow-dose computed tomographyLung cancer screeningCD4 cell countMedicaid Services criteriaCancer screeningLung cancerMortality reductionCell countLDCT examinationsAnnual low-dose computed tomographyUninfected individualsLung cancer mortality reductionVeterans Aging Cohort StudyCancer mortality reductionAntiretroviral therapy adherenceAging Cohort StudyLung cancer mortalityCells/Lung Cancer Policy ModelMultiple national organizationsAlternative screening strategiesBase-case analysisHIV cohortCohort studyFormer smokers
2014
Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery
Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fätkenheuer G, Gutiérrez F, Raffi F, Kirk O, Mary-Krause M, Stephan C, de Olalla PG, Guest J, Samji H, Castagna A, Monforte A, Skaletz-Rorowski A, Ramos J, Lapadula G, Mussini C, Force L, Meyer L, Lampe F, Boufassa F, Bucher HC, De Wit S, Burkholder GA, Teira R, Justice AC, Sterling TR, Crane H, Gerstoft J, Grarup J, May M, Chêne G, Ingle SM, Sterne J, Obel N, EuroCoord F, Engsig F, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fätkenheuer G, Gutiérrez F, Raffi F, Kirk O, Mary-Krause M, Stephan C, de Olalla P, Guest J, Samji H, Castagna A, Monforte A, Skaletz-Rorowski A, Ramos J, Lapadula G, Mussini C, Force L, Meyer L, Lampe F, Boufassa F, Bucher H, De Wit S, Burkholder G, Teira R, Justice A, Sterling T, Crane H, Gerstoft J, Grarup J, May M, Chêne G, Ingle S, Sterne J, Boulle A, Brodt H, Casabona J, Cavassini M, Chêne G, Costagliola D, Dabis F, Monforte A, del Amo J, Van Sighem A, Fätkenheuer G, Gill J, Guest J, Haerry D, Hogg R, Justice A, Mocroft A, Obel N, Kitahata M, Lampe F, Reiss P, Saag M, Sterling T, Teira R, Williams M, Zangerle R, Ingle S, May M, Sterne J, Zangerle R, Touloumi G, Warszawski J, Meyer L, Dabis F, Krause M, Ghosn J, Leport C, Reiss P, Wit F, Prins M, Bucher H, Sabin C, Gibb D, Fätkenheuer G, Del Amo J, Obel N, Thorne C, Mocroft A, Kirk O, Stephan C, Pérez-Hoyos S, Hamouda O, Gussenheimer-Bartmeyer B, Noguera-Julian A, Antinori A, Monforte A, Brockmeyer N, Ramos J, Battegay M, Rauch A, Mussini C, Tookey P, Casabona J, Miró J, Castagna A, de Wit S, Goetghebuer T, Torti C, Teira R, Garrido M, Judd A, Conejo P, Haerry D, Weller I, Casabona J, Costagliola D, d'Arminio-Monforte A, Battegay M, de Wit S, Del Amo J, Grarup J, Chêne G, Colin C, Schwimmer C, Termote M, Kjaer J, Campbell M, Raben D, Battegay M, Bohlius J, Bouteloup V, Bucher H, Cozzi-Lepri A, Dabis F, Monforte A, del Amo J, Dorrucci M, Egger M, Engsig F, Furrer H, Judd A, Kirk O, Lambotte O, Lewden C, Lodi S, Lodwick R, Matheron S, Meyer L, Miro J, Mocroft A, Monge S, Nakagawa F, Obel N, Paredes R, Phillips A, Puoti M, Reekie J, Sabin C, Scherrer A, Smit C, Sterne J, Thiebaut R, Thorne C, Torti C, Touloumi G, Wittkop L. Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clinical Infectious Diseases 2014, 58: 1312-1321. PMID: 24457342, PMCID: PMC6276895, DOI: 10.1093/cid/ciu038.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyIncomplete CD4 recoveryCD4 countLong-term mortalityHIV-positive individualsViral suppressionRisk factorsCD4 recoveryInitiation of cARTLow initial CD4 countsCD4 cell recoveryLow CD4 countSustained viral suppressionInitial CD4 countHuman immunodeficiency virusCause of deathDifferent patient groupsCART initiationAntiretroviral therapyHIV cohortCox regressionImmunodeficiency virusPatient groupEligible individualsSubsequent mortality
2013
Validation of an algorithm to identify antiretroviral‐naïve status at time of entry into a large, observational cohort of HIV‐infected patients
Gandhi NR, Tate JP, Rodriguez‐Barradas M, Rimland D, Goetz MB, Gibert C, Brown ST, Mattocks K, Justice AC. Validation of an algorithm to identify antiretroviral‐naïve status at time of entry into a large, observational cohort of HIV‐infected patients. Pharmacoepidemiology And Drug Safety 2013, 22: 1019-1025. PMID: 23836591, PMCID: PMC3831617, DOI: 10.1002/pds.3476.Peer-Reviewed Original ResearchConceptsART-naïve patientsViral load thresholdMedical record reviewAntiretroviral treatmentMedical recordsHIV cohortObservational cohortRecord reviewVeterans Aging Cohort Study Virtual CohortVirtual cohortPrevious antiretroviral treatmentLaboratory dataPatients' medical recordsPositive predictive value 87Cohort entryAdverse eventsHIV outcomesRandomized trialsRetrospective studyAdverse reactionsTime of entryCopies/ART treatmentTreatment statusTreatment history
2009
Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements
Lanoy E, May M, Mocroft A, Phillip A, Justice A, Chêne G, Furrer H, Sterling T, Monforte A, Force L, Gill J, Harris R, Hogg R, Rockstroh J, Saag M, Khaykin P, de Wolf F, Sterne J, Costagliola D. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS 2009, 23: 2199-2208. PMID: 19779320, PMCID: PMC3122149, DOI: 10.1097/qad.0b013e3283305a00.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyCD4 cell countHIV-1-infected patientsHIV-1 RNAViral loadCART initiationCell countStart of cARTHIV-1 RNA measurementsART Cohort CollaborationMedian CD4 cellPredictors of AIDSRates of AIDSImportant prognostic factorPrognosis of patientsCohort CollaborationSubsequent AIDSAntiretroviral therapyHIV cohortCD4 cellsPrognostic factorsPrognostic importanceCopies/PatientsAIDS
2006
Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort
Braitstein P, Justice A, Bangsberg DR, Yip B, Alfonso V, Schechter MT, Hogg RS, Montaner J. Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort. AIDS 2006, 20: 323-331. PMID: 16439865, DOI: 10.1097/01.aids.0000198091.70325.f4.Peer-Reviewed Original ResearchConceptsInjection drug useAntiretroviral treatmentAntiretroviral therapyLiver injuryHigher plasma albumin levelCombination antiretroviral treatmentHepatitis C serostatusHepatitis C coinfectionPlasma albumin levelsMultivariate logistic regressionDrug treatment programsHIV/AIDSHCV seropositivityC coinfectionHCV antibodiesHIV cohortHCV serologyAlbumin levelsLow albuminPrimary outcomePrescription refillsPoor adherenceMale genderHIV therapyEligible individuals
2004
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes
Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, Mussini C, Wit F, d'Arminio Monforte A, Weber R, Fusco G, Staszewski S, Law M, Hogg R, Lampe F, Gill MJ, Castelli F, Phillips AN. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. The Lancet 2004, 364: 51-62. PMID: 15234856, DOI: 10.1016/s0140-6736(04)16589-6.Peer-Reviewed Original ResearchConceptsProportional hazards modelVirological failureCD4 cell count slopesHIV-1 RNA concentrationsCox proportional hazards modelCD4 cell countPredictors of deathAntiretroviral therapyHIV cohortDual therapyClinical outcomesViral loadHIV replicationDrug classesTreatment strategiesTreatment informationPatientsDemographic characteristicsRNA concentrationRegression analysisTherapyFailureCohort